Combination of temsirolimus (CCI-779) with chemo-radiation in newly diagnosed GBM (NCCTG trial N027D) is associated with increased infectious risks

PURPOSE: The mammalian target of rapamycin (mTOR) functions within the PI3K/Akt signaling pathway as a critical modulator of cell survival. METHODS: The mTOR inhibitor temsirolimus (CCI-779) was combined with chemo-radiotherapy in GBM patients in a dose-escalation Phase I trial. The first 12 patient...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Sarkaria, Jann N., Galanis, Eva, Wu, Wenting, Dietz, Allan B., Kaufmann, Timothy J., Gustafson, Michael P., Brown, Paul D., Uhm, Joon H., Rao, Ravi D., Doyle, Laurence, Giannini, Caterina, Jaeckle, Kurt A., Buckner, Jan C.
Formato: Artigo
Idioma:Inglês
Publicado: 2010
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2982871/
https://ncbi.nlm.nih.gov/pubmed/20921209
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-1453
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares